Scholarlink

Purpose <p>This study aims to explore the genetic anomalies (excluding aneuploidy) associated with Müllerian duct anomalies (MDA). This project is part of a large uterine transplantation (UTx) program, where women with MRKH (Mayer-Rokitansky-Küster-Hauser) syndrome are the primary candidates. The potential of the hereditary nature of MDA was evaluated to facilitate appropriate genetic counseling when applicable.</p> Methods <p>We used chromosome microarray analysis (CMA) and exome sequencing (ES) to identify genetic variations that may contribute to the phenotype of MDA. A comprehensive description of the genital and extra-genital phenotype was established for each individual in whom a potentially relevant genetic variant has been identified.</p> Results <p>We analyzed data from 3 fetuses and 75 women with MDA. All individuals had CMA and 65 ES were analyzed. CMA identified 6 copy number variations (CNVs) of interest (diagnostic yield: 7.7%), notably the recurrent 17q12 deletion. In 13.8% of individuals, ES revealed likely pathogenic or pathogenic variants that fully explained the phenotype in affected individuals, variants of uncertain significance (VUS) of interest in the pathology, or variants unrelated to MDA but linked to other symptoms presented by the individuals.</p> Conclusion <p>The findings underscore the crucial role of genetics in understanding and managing MDA. With the emergence of UTx, assessing the risk of transmission and recurrence of genetic anomalies is essential. In addition, genetic analysis may enable early medical prevention for associated phenotypes. Genetic analysis is therefore becoming an essential component of the clinical assessment and counseling for women with MDA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic analyses using chromosomal microarray and exome sequencing in fetuses and women with Müllerian duct anomalies

  • 期刊论文

  • 发表日期：

    2025年10月21日

查看全文
  • Auriane Cospain,
  • Paul Rollier,
  • Anna Lokchine,
  • Erika Launay,
  • Ludivine Dion,
  • Alinoé Lavillaureix,
  • Godelieve Morel,
  • Laura Mary,
  • Laurent Pasquier,
  • Chloé Quelin,
  • Fabrice G. Petit,
  • Soazik P. Jamin,
  • Mélanie Fradin,
  • Bénédicte Nouyou,
  • Wilfrid Carré,
  • Régis Bouvet,
  • Lenaick Detivaud Gauthier,
  • Daniel Guerrier,
  • Marie Faoucher,
  • Christèle Dubourg,
  • Sylvie Odent,
  • Marc-Antoine Belaud Rotureau,
  • Vincent Lavoue,
  • Sylvie Jaillard

摘要

Purpose

This study aims to explore the genetic anomalies (excluding aneuploidy) associated with Müllerian duct anomalies (MDA). This project is part of a large uterine transplantation (UTx) program, where women with MRKH (Mayer-Rokitansky-Küster-Hauser) syndrome are the primary candidates. The potential of the hereditary nature of MDA was evaluated to facilitate appropriate genetic counseling when applicable.

Methods

We used chromosome microarray analysis (CMA) and exome sequencing (ES) to identify genetic variations that may contribute to the phenotype of MDA. A comprehensive description of the genital and extra-genital phenotype was established for each individual in whom a potentially relevant genetic variant has been identified.

Results

We analyzed data from 3 fetuses and 75 women with MDA. All individuals had CMA and 65 ES were analyzed. CMA identified 6 copy number variations (CNVs) of interest (diagnostic yield: 7.7%), notably the recurrent 17q12 deletion. In 13.8% of individuals, ES revealed likely pathogenic or pathogenic variants that fully explained the phenotype in affected individuals, variants of uncertain significance (VUS) of interest in the pathology, or variants unrelated to MDA but linked to other symptoms presented by the individuals.

Conclusion

The findings underscore the crucial role of genetics in understanding and managing MDA. With the emergence of UTx, assessing the risk of transmission and recurrence of genetic anomalies is essential. In addition, genetic analysis may enable early medical prevention for associated phenotypes. Genetic analysis is therefore becoming an essential component of the clinical assessment and counseling for women with MDA.